NEW YORK, Nov. 11 NY-Cynvec-LLC-Present
NEW YORK, Nov. 11 /PRNewswire/ -- Cynvec LLC, a privately-held
biopharmaceutical company focused on developing novel cancer therapies that
harness the apoptotic ability of the Sindbis viral vector, today announced
that executive management will participate in the Rodman & Renshaw 10th Annual
Healthcare Conference to be held November 10 through November 12, 2008 at the
New York Palace Hotel in New York City. Frank D. Stonebanks, President and
Chief Executive Officer, is scheduled to present an overview of the company at
12:00 p.m. ET on Tuesday, November 11, 2008.
The presentation will be webcast live and archived on the company's
website at http://www.cynvec.com.
About Cynvec LLC
Cynvec was founded in 2004 and is a development stage biotech company
based in New York City. The Company is focused on developing Sindbis-based
viral vectors as standalone oncolytic therapeutics, delivery systems for
monoclonal antibodies and cytokines as well as cancer diagnostic products.
The Sindbis vector system, originally developed at NYU School of Medicine,
represents a unique, patented platform technology for numerous commercial
applications. The company is developing therapies to treat a number of tumor
types, including ovarian, pancreatic, GI, liver, colorectal, and other cancers
where the laminin receptor is overexpressed. The Company's lead product, CYN
101, is in late pre-clinical development, and has shown statistically
significant survival rates in both ovarian and pancreatic cancer models.
Further information on Cynvec can be found at http://www.cynvec.com.
SOURCE Cynvec LLC
